10X Genomics

10X Genomics

10X Genomics is a life-science technology company headquartered in Pleasanton, California. Its founding story centers on commercializing high-throughput single-cell and spatial biology tools, though the exact founding year and founding team are not publicly detailed in accessible sources. The firm's product suite spans four platforms: Chromium for single-cell multiomics, Visium for spatial gene expression, Xenium for in situ analysis, and Atera for whole-transcriptome spatial profiling at subcellular resolution. Its tools are used across drug development, oncology, and immunology research, where the company claims they help reveal how tumors adapt and how immune cells misfire. 10X Genomics does not disclose AUM, deployment figures, or investment-stage coverage, as it is an operating company, not an investment vehicle. The firm employs a global sales network with dedicated contacts for North America, Europe, and Asia, and a distributor partner program. It reported over 10,000 publications citing its products as of mid-2026. No recent operational event was publicly found in the last 24 months that informs current posture. 10X Genomics is structurally distinct from family offices and asset managers: it is a commercial supplier of research instruments and consumables. Its relationship with capital comes through sales to academic and pharmaceutical customers, not through fund commitments or direct deals.